it may help you to remember this is a public company and Novartis could buy a controlling stock , install their directors, put pressure thru arbitrage on the stock and walk away with the company. maybe not in that order or as simplistic.
you know - the people with money make the rules...
MNTA: As a mnta shareholder, I'd rather see MNTA independent. I can't see NVS offering anything close to full value yet. Too many question marks. The potential is immense if 3 years from now MNTA retains sole generic status of Lovenox and Copaxone. Could equal 800 to 900 million in yearly revenue. If NVS offers 3.5 to 4 billion then I listen. Call me greedy. But even though the engine is running, MNTA hasn't even gotten off the ground yet.
Market Data 
Markets 
AI
